1 Prologue
1.1.1 Pipeline Molecules Analysis 14
1.1.2 Patent Expiry 14
1.1.3 Market opportunity Analysis 14
2 Market Introduction
2.1 Scope of Study 15
2.2 Research Objective 15
2.3 Assumptions & Limitations 15
2.3.1 Assumptions 15
2.3.2 Limitations 15
2.4 Market Structure 16
3 Research Methodology
3.1.1 Analysis of Historical Data Trends: 18
3.1.2 Secondary Research Methodology 18
3.1.3 Analysis of Forecast data: 18
3.1.4 Primary Research Methodology 19
3.1.5 Secondary Research Methodology 20
3.1.6 Market Share Analysis 22
3.1.7 Trade Analysis 22
3.1.8 Market Pricing Approach 22
4 Market Dynamics
4.1 Drivers 23
4.1.1 Growing Awareness (Impact Weightage โ 35 %) 23
4.1.1.1 Facts and information 23
4.1.1.2 Interpretation 23
4.1.1.3 Impact 23
4.1.1.4 Growth Enhancement Factor 23
4.1.1.5 Conclusion 24
4.2 Increase in the prevalence of MRSA infections and number of hospital (Impact Weightage โ 35 %) 24
4.2.1.1 Facts and Information 24
4.2.1.2 Interpretation 24
4.2.1.3 Impact 24
4.2.1.4 Conclusion 25
4.2.2 Increase in Population and Especially Elderly and Immuno-Compromised Population (Impact Weightage โ 30 %) 25
4.2.2.1 Facts and Information 25
4.2.2.2 Interpretation 25
4.2.2.3 Impact 25
4.2.2.4 Growth Enhancement Factor 25
4.2.2.5 Conclusion 25
4.3 Restraints 26
4.3.1 Cost of Novel MRSA Drugs (Impact Weightage - 65 %) 26
4.3.2 Facts and Information 26
4.3.3 Interpretation 26
4.3.4 Impact 26
4.3.5 Conclusion 26
4.3.6 Hospital Readmissions Reduction Program will Result in Greater Market Opportunity (Impact Weightage - 35 %) 26
4.3.6.1 Facts and Information 26
4.3.6.2 Impact 26
4.3.6.3 Conclusion 27
4.4 Opportunities 27
4.4.1 Research and Development 27
4.4.2 Developing Regions as a Base for Production 27
4.4.3 Strategic Alliances, will be the Key Growth Drivers for MRSA Market. 27
4.5 Challenges:- Increase in Competition Between Innovators Vs. Generic Drugs Leads to Price Competition 28
4.5.1 Rising Resistance to MRSA Drugs 28
4.6 Additional Points Such as Loss of Patents 28
4.6.1 Loss of Patents: Daptomycin is Expected to Lose Patent Protection in 2017 28
4.6.1.1 Facts and Information 28
4.6.1.2 Interpretation 28
4.6.1.3 Impact 29
4.6.1.4 Conclusion 29
4.7 Technology Trends And Assessment 29
5 Market Factor Analysis
5.1 Supply Chain Analysis 30
5.1.1 Raw Material 30
5.1.2 Supplier 31
5.1.3 Manufacturer 32
5.1.4 Distributer 33
5.1.5 Customer 34
5.1.6 Consumer 34
5.1.6.1 Segmentation. 35
5.1.6.2 Agility 35
5.2 Porterโs Five Force Analysis 36
5.2.1 Threat from a New Entrant 37
5.2.2 Bargaining Power of Buyer 37
5.2.3 Bargaining Power of Supplier 38
5.2.4 Threat from substitute 38
5.2.5 Intensity of Competitive Rivalry 39
5.3 Investment Opportunity Analysis 40
5.3.1 Market Size (Current and Future), Growth Rate and Profitability 40
5.3.2 Investment Risks 40
5.3.3 Market Outlook 41
5.3.4 Government Involvement 42
5.3.5 Income Level and Regional Variations 42
5.3.6 Competitors 43
5.3.7 Projections 43
5.4 Merger And Acquisitions 44
5.4.1 Strategies for Mergers and Acquisitions 44
5.4.1.1 Faster Access to the Antibiotics Market and Access to Skills and Technology 44
5.4.1.2 High Investibles Balance Sheet Funds and Patent Decline 45
5.4.1.3 Faster FDA Approvals and Unmet and Unserved Needs 45
5.4.1.4 Economics of Co-Development and Sharing of Assets and Technological Expertise 45
5.5 Molecule Analysis 46
5.5.1 Introduction 46
5.5.2 Vancomycin 46
5.5.3 Linezolid 46
5.5.4 Daptomycin 47
5.5.5 Tigecycline 47
5.6 Future trend 47
6 Global MRSA Drugs Market By Drug Class
6.1 Introduction 48
6.2 Sulfa drugs 50
6.3 Tetracyclines 50
6.4 Oxazolidinones 51
6.5 Folate Antagonists 51
6.6 Lipopeptide 51
6.7 Glycopeptide Antibiotics 51
6.6 Others 52
7 Global MRSA Drugs Market By MRSA Types
7.1 Introduction 53
7.2 Hospital-acquired (HA-MRSA) 54
7.3 Community-acquired (CA-MRSA) 54
8 Global MRSA Drugs Market By Disease Indication
8.1 Introduction 55
8.2 Skin infections 56
8.3 Bone and Joint Infections 57
8.4 Bacteremia 57
8.5 Animal Infections 58
8.6 Others 58
9 Global MRSA Drugs Market By End Users
9.1 Introduction 59
9.2 Hospitals and Clinics 60
9.3 Research and Academics 60
9.4 Others 61
10 Global MRSA Market By Region
10.1 Introduction 62
10.2 North America 63
10.2.1 US 67
10.2.2 Canada 70
10.3 Europe 73
10.3.1 Germany 77
10.3.2 France 80
10.3.3 UK 83
10.3.4 Italy 86
10.3.5 Spain 89
10.3.6 Rest of Europe 92
10.4 Asia-Pacific 95
10.4.1 Japan 99
10.4.2 China 102
10.4.3 India 105
10.4.4 Republic of Korea 108
10.4.5 Australia 111
10.4.6 Rest of Asia-Pacific 114
10.5 Middle East and Africa 117
10.5.1 Middle East 121
10.5.2 Africa 124
11 Company landscape
12 Company Profiling
12.1 Merck KGaA 128
12.1.1 Company Overview 128
12.1.2 Financials 128
12.1.3 Products 128
12.1.4 Key Developments 128
12.2 Olon 129
12.2.1 Company Overview 129
12.2.2 Financials 129
12.2.3 Products 129
12.2.4 Key Developments 129
12.3 Allergan 130
12.3.1 Company Overview 130
12.3.2 Financials 130
12.3.3 Products 130
12.3.4 Key Developments 130
12.4 Baxter 131
12.4.1 Company Overview 131
12.4.2 Financials 131
12.4.3 Products 131
12.4.4 Key Developments 131
12.5 Theravance Biopharma 132
12.5.1 Company Overview 132
12.5.2 Financials 132
12.5.3 Products 132
12.5.4 Key Developments 132
12.6 Pfizer 133
12.6.1 Company Overview 133
12.6.2 Financials 133
12.6.3 Products 133
12.6.4 Key Developments 133
12.7 Mylan NV 134
12.7.1 Company Overview 134
12.7.2 Financials 134
12.7.3 Products 134
12.7.4 Key Developments 134
12.8 Novartis 135
12.8.1 Company Overview 135
12.8.2 Financials 135
12.8.3 Products 135
12.8.4 Key Developments 135
13 Conclusion
13.1 Key Findings 136
13.1.1 CEOโs Viewpoint 136
13.1.2 Unmet Needs 136
13.1.3 Key Companies To Watch 136
13.1.4 Prediction 136
14 List of Tables
TABLE 1 PRIMARY INTERVIEWS 19
TABLE 2 SAMPLE SIZE DETERMINATION OF END-USERS (HOSPITALS, CLINICS) 20
TABLE 3 GLOBAL MRSA DRUGS MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 48
TABLE 4 GLOBAL MRSA DRUGS MARKET FOR SULFA DRUGS, USD MILLION (2020 TO 2027) 50
TABLE 5 GLOBAL MRSA DRUGS MARKET FOR TETRACYCLINES, USD MILLION (2020 TO 2027) 50
TABLE 6 GLOBAL MRSA DRUGS MARKET FOR OXAZOLIDINONES, USD MILLION (2020 TO 2027) 51
TABLE 7 GLOBAL MRSA DRUGS MARKET FOR GLYCOPEPTIDE ANTIBIOTICS, USD MILLION (2020 TO 2027) 51
TABLE 8 GLOBAL MRSA DRUGS MARKET FOR OTHERS, USD MILLION (2020 TO 2027) 52
TABLE 9 GLOBAL MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 53
TABLE 10 GLOBAL MRSA DRUGS MARKET FOR HOSPITAL-ACQUIRED (HA-MRSA), USD MILLION (2020 TO 2027) 54
TABLE 11 GLOBAL MRSA DRUGS MARKET FOR COMMUNITY-ACQUIRED (CA-MRSA), USD MILLION (2020 TO 2027) 54
TABLE 12 GLOBAL MRSA DRUGS MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 55
TABLE 13 GLOBAL MRSA DRUGS MARKET FOR SKIN INFECTIONS, USD MILLION (2020 TO 2027) 56
TABLE 14 GLOBAL MRSA DRUGS MARKET FOR BONE AND JOINT INFECTIONS, USD MILLION (2020 TO 2027) 57
TABLE 15 GLOBAL MRSA DRUGS MARKET FOR BACTEREMIA, USD MILLION (2020 TO 2027) 57
TABLE 16 GLOBAL MRSA DRUGS MARKET FOR ANIMAL INFECTIONS, USD MILLION (2020 TO 2027) 58
TABLE 17 GLOBAL MRSA DRUGS MARKET FOR OTHER, USD MILLION (2020 TO 2027) 58
TABLE 18 GLOBAL MRSA DRUGS MARKET BY END USERS, USD MILLION (2020 TO 2027) 59
TABLE 19 GLOBAL MRSA DRUGS MARKET FOR HOSPITALS AND CLINICS, USD MILLION (2020 TO 2027) 60
TABLE 20 GLOBAL MRSA DRUGS MARKET FOR RESEARCH AND ACADEMICS, USD MILLION (2020 TO 2027) 60
TABLE 21 GLOBAL MRSA DRUGS MARKET FOR OTHERS, USD MILLION (2020 TO 2027) 61
TABLE 22 GLOBAL MRSA MARKET BY REGION, 2020 TO 2027, USD MILLION (2020 TO 2027) 62
TABLE 23 NORTH AMERICA MRSA MARKET BY COUNTRY, USD MILLION (2020 TO 2027) 63
TABLE 24 NORTH AMERICA MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 64
TABLE 25 NORTH AMERICA MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 65
TABLE 26 NORTH AMERICA MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 65
TABLE 27 NORTH AMERICA MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 66
TABLE 28 US MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 67
TABLE 29 US MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 68
TABLE 30 US MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 68
TABLE 31 US MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 69
TABLE 32 CANADA MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 70
TABLE 33 CANADA MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 71
TABLE 34 CANADA MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 71
TABLE 35 CANADA MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 72
TABLE 36 EUROPE MRSA DRUG MARKET BY REGION, USD MILLION (2020 TO 2027) 73
TABLE 37 EUROPE MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 74
TABLE 38 EUROPE MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 75
TABLE 39 EUROPE MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 75
TABLE 40 EUROPE MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 76
TABLE 41 GERMANY MRSA DRUG MARKET BY DRUG CLASS, GERMANY USD MILLION (2020 TO 2027) 77
TABLE 42 GERMANY MRSA DRUG MARKET BY MRSA TYPES, GERMANY USD MILLION (2020 TO 2027) 78
TABLE 43 GERMANY MRSA DRUG MARKET BY DISEASE INDICATION, GERMANY USD MILLION (2020 TO 2027) 78
TABLE 44 GERMANY MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 79
TABLE 45 FRANCE MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 80
TABLE 46 FRANCE MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 81
TABLE 47 FRANCE MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 81
TABLE 48 FRANCE MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 82
TABLE 49 UK MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 83
TABLE 50 UK MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 84
TABLE 51 UK MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 84
TABLE 52 UK MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 85
TABLE 53 ITALY MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 86
TABLE 54 ITALY MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 87
TABLE 55 ITALY MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 87
TABLE 56 ITALY MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 88
TABLE 57 SPAIN MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 89
TABLE 58 SPAIN MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 90
TABLE 59 SPAIN MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 90
TABLE 60 SPAIN MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 91
TABLE 61 REST OF EUROPE MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 92
TABLE 62 REST OF EUROPE MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 93
TABLE 63 REST OF EUROPE MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 93
TABLE 64 REST OF EUROPE MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 94
TABLE 65 ASIA-PACIFIC MRSA DRUG MARKET BY REGION, USD MILLION (2020 TO 2027) 95
TABLE 66 ASIA-PACIFIC MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 96
TABLE 67 ASIA-PACIFIC MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 97
TABLE 68 ASIA-PACIFIC MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 97
TABLE 69 ASIA-PACIFIC MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 98
TABLE 70 JAPAN MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 99
TABLE 71 JAPAN MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 100
TABLE 72 JAPAN MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 100
TABLE 73 JAPAN MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 101
TABLE 74 CHINA MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 102
TABLE 75 CHINA MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 103
TABLE 76 CHINA MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 103
TABLE 77 CHINA MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 104
TABLE 78 INDIA MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 105
TABLE 79 INDIA MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 106
TABLE 80 INDIA MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 106
TABLE 81 INDIA MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 107
TABLE 82 SOUTH KOREA MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 108
TABLE 83 SOUTH KOREA MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 109
TABLE 84 SOUTH KOREA MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 109
TABLE 85 SOUTH KOREA MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 110
TABLE 86 AUSTRALIA MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 111
TABLE 87 AUSTRALIA MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 112
TABLE 88 AUSTRALIA MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 112
TABLE 89 AUSTRALIA MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 113
TABLE 90 REST OF ASIA-PACIFIC MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 114
TABLE 91 REST OF ASIA-PACIFIC MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 115
TABLE 92 REST OF ASIA-PACIFIC MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 115
TABLE 93 REST OF ASIA-PACIFIC MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 116
TABLE 94 MIDDLE EAST AND AFRICA MRSA DRUG MARKET BY REGION, USD MILLION (2020 TO 2027) 117
TABLE 95 MIDDLE EAST AND AFRICA MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 118
TABLE 96 MIDDLE EAST AND AFRICA MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 119
TABLE 97 MIDDLE EAST AND AFRICA MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 119
TABLE 98 MIDDLE EAST AND AFRICA MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 120
TABLE 99 MIDDLE EAST MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 121
TABLE 100 MIDDLE EAST MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 122
TABLE 101 MIDDLE EAST MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 122
TABLE 102 MIDDLE EAST MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 123
TABLE 103 AFRICA MRSA DRUG MARKET BY DRUG CLASS, USD MILLION (2020 TO 2027) 124
TABLE 104 AFRICA MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 TO 2027) 125
TABLE 105 AFRICA MRSA DRUG MARKET BY DISEASE INDICATION, USD MILLION (2020 TO 2027) 125
TABLE 106 AFRICA MRSA DRUG MARKET BY END USERS, USD MILLION (2020 TO 2027) 126
15 List of Figures
FIGURE 1 GLOBAL MRSA DRUGS MARKET, 2020 TO 2027 (USD MILLION) 12
FIGURE 2 GLOBAL MRSA DRUGS MARKET BY REGION, 2020 & 2027 (USD MILLION) 13
FIGURE 3 GLOBAL MRSA DRUGS MARKET: MARKET STRUCTURE 16
FIGURE 4 RESEARCH METHODOLOGY 17
FIGURE 5 FORCASTING MODEL 21
FIGURE 6 GLOBAL MRSA DRUGS MARKET: PORTER FIVE FORCES ANALYSIS 36
FIGURE 7 GLOBAL MRSA DRUGS MARKET SHARE, 2020 (%) 46
FIGURE 8 GLOBAL MRSA DRUGS MARKET BY DRUG CLASS, USD MILLION (2020 & 2027) 49
FIGURE 9 GLOBAL MRSA DRUG MARKET BY MRSA TYPES, USD MILLION (2020 & 2027) 53
FIGURE 10 GLOBAL MRSA DRUGS MARKET BY DISEASE INDICATION, 2020 & 2027 56
FIGURE 11 GLOBAL MRSA DRUGS MARKET BY END USERS, 2020 & 2027 59
FIGURE 12 GLOBAL MRSA MARKET SHARE BY REGION, 2020 (%) 62
FIGURE 13 NORTH AMERICA MRSA MARKET SHARE BY REGION, 2020 (%) 63
FIGURE 14 ASIA-PACIFIC MRSA DRUG MARKET SHARE BY REGION, 2020 (%) 73
FIGURE 15 ASIA-PACIFIC MRSA DRUG MARKET SHARE BY REGION, 2020 (%) 95
FIGURE 16 MIDDLE EAST AND AFRICA MRSA DRUG MARKET SHARE BY REGION, 2020 (%) 117
FIGURE 17 MAJOR PLAYERS & MARKET SHARE OF MRSA DRUGS, 2020 (%) 127
